Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Western Alliance Bancorporation WAL | Citadel Advisors LLC | 2,705,253 2.500% | -3,230,285 (-54.42%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Allakos Inc. ALLK | Citadel Advisors LLC | 3,304,622 3.800% | -1,462,307 (-30.68%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Icosavax, Inc. ICVX | Citadel Advisors LLC | 283,079 0.600% | -1,906,390 (-87.07%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Coherus Oncology, Inc. CHRS | Citadel Advisors LLC | 2,047,286 1.800% | -3,767,788 (-64.79%) | Filing History |
| 2024-02-14 4:58 pm Purchase | 2023-12-31 | 13G | Janux Therapeutics, Inc. JANX | Citadel Advisors LLC | 3,125,897 6.800% | 999,762 (+47.02%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Nektar Therapeutics NKTR | Citadel Advisors LLC | 375,675 3.000% | -272,975 (-42.08%) | Filing History |
| 2024-02-14 4:58 pm Purchase | 2023-12-31 | 13G | Dutch Bros Inc. BROS | Citadel Advisors LLC | 4,073,886 6.500% | 865,013 (+26.96%) | Filing History |
| 2024-02-14 4:58 pm Purchase | 2023-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | Citadel Advisors LLC | 5,406,089 7.600% | 1,819,325 (+50.72%) | Filing History |
| 2024-02-14 4:58 pm Purchase | 2023-12-31 | 13G | Expensify, Inc. EXFY | Citadel Advisors LLC | 2,794,376 4.000% | 82,713 (+3.05%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Catcha Investment Corp CHAA | Citadel Advisors LLC | 6,410 0.300% | -2,198,479 (-99.71%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Project Energy Reimagined Acquisition Corp. PEGR | Citadel Advisors LLC | 172,489 1.000% | -2,043,562 (-92.22%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Spruce Biosciences, Inc. SPRB | Citadel Advisors LLC | 1,443 0.300% | -21,855 (-93.81%) | Filing History |
| 2024-02-14 4:57 pm Purchase | 2023-12-31 | 13G | Ventyx Biosciences, Inc. VTYX | Citadel Advisors LLC | 4,279,553 7.300% | 490,758 (+12.95%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Vera Therapeutics, Inc. VERA | Citadel Advisors LLC | 43,447 0.100% | -1,948,106 (-97.82%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Vigil Neuroscience, Inc. VIGL | Citadel Advisors LLC | 2,161,902 6.000% | -2,014 (-0.09%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Citadel Advisors LLC | 2,084,267 7.800% | -8,221 (-0.39%) | Filing History |
| 2024-02-14 4:57 pm Purchase | 2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | Citadel Advisors LLC | 1,556,842 5.200% | 219,849 (+16.44%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | Citadel Advisors LLC | 3,738,482 5.300% | -101,347 (-2.64%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | VYNE Therapeutics Inc. VYNE | Citadel Advisors LLC | 1,181,144 8.500% | -23 (-0.00%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Korro Bio, Inc. KRRO | Citadel Advisors LLC | 529,251 6.600% | -16,967 (-3.11%) | Filing History |